16-18 MeV Segment to Lead Medical Cyclotron Market During 2022-2028

According to our latest study, "Medical Cyclotron Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Type, Capacity, and End User," the Medical Cyclotron market size is projected to grow from US$ 202.34 million in 2022 to US$ 332.49 million by 2028; it is estimated to grow at a CAGR of 8.6% from 2022 to 2028. The report highlights the key factors driving the market and prominent players with their developments. The increasing prevalence of cancer and growing inclination toward nuclear scans for accurate diagnosis is driving the market growth. However, the high cost of procedures and lack of expertise are hindering the market's growth.

A cyclotron is a particle accelerator and is an electrically powered machine that produces a beam of charged particles used for industrial, research, and medical purposes. In medical applications, cyclotrons produce beams that are used to manufacture radioisotopes for medical imaging. Various medical cyclotrons are being used to produce SPECT (Single photon emission computed tomography) and Positron Emission Tomography (PET) isotopes used for therapeutic and other medical applications. Cyclotrons can be used in particle therapy to treat cancer with the help of ion beams that can penetrate the body and kill the tumors with the help of radiation.

Nuclear medicine is a highly specialized area that develops and uses instruments and radiopharmaceuticals to investigate the physiological processes of patients as well as diagnose diseases noninvasively. Nuclear medicines are used to cure diseases, including cancer, heart disease, psychiatric conditions, and gastrointestinal diseases. These medicines can diagnose several disorders that may require surgery, biopsy, or other invasive diagnostic tests. Moreover, 1 in 5 patients is using nuclear medicines per year, and 1 in 10 are using radioactive sources. According to the World Nuclear Association, about 40 million procedures are carried out globally with nuclear medicines, with an annual growth of 5% per annum. It is estimated that one in fifty patients in developed economies use nuclear medicines for diagnosis each year, and one-tenth of this population is treated with radioisotopes. Consequently, the number of patients using nuclear diagnostics is expected to increase soon due to their accuracy, significantly pushing the market growth. Furthermore, the rising number of PET cyclotrons and the closing of nuclear reactors such as the Tomari nuclear plant in Japan are augmenting the market growth. The introduction of advanced devices with a built-in shield and technological compatibility with PET and SPECT devices is responsible for an increase in the acceptability of these devices. The rising acceptability of cyclotrons is poised to escalate the market's growth. Moreover, the high prevalence of cardiovascular diseases (CVDs) propels the market growth for nuclear medicines. CVDs have been reported to cause more than 17.9 million deaths annually worldwide. Targeted treatments for a particular disease are easy to implement in clinics, and high efficacy and lesser side effects of the molecular imaging approach are the main advantages of personalized medicines. Among differentiated cancer types, thyroid cancer is one of the most common diagnostic or therapeutic types. Molecular imaging plays an important role in diagnosing and treating thyroid cancer. It aids visual representation, classification, and quantification of biological characteristics of cells and tissues in patients; using these methods, healthcare providers can also provide personalized health management. Thus, the results of multimodal nuclear imaging could be used to develop a lesion-based strategy for patients with multiple heterogeneous metastatic lesions.

Based on capacity, the medical cyclotron market is segmented into 10-12 MeV, 16-18 MeV, 19-24 MeV, and 24 MeV and above. The 16-18 MeV segment will hold the largest share of the market in 2022. The same segment is estimated to register the highest CAGR of 9.1% during the forecast period. The 16-18 MeV range is generally used for small medical cyclotrons, capable of producing considerable quantities of Technetium-99m (99mTc). For instance, GE Healthcare offers PETtrace 800 series cyclotrons that operate at 16.5 MeV protons and has maximum acceleration beam intensity of 130 ?A. This range of energy is widely accepted as it offers maximum capacity and consistent yields. Due to its compact size, it utilizes small space and is installed easily and quickly. The 16-18 MeV range is generally used to produce an 18F-Fluoride radio particle. These are also accounted for as compact medical cyclotrons with self-shielding to reduce neutron fluxes. 18 MeV are unshielded cyclotrons, and 16.5-MeV are self-shielded cyclotrons.

General Electric Company; Best ABT Molecular Imaging, Inc.; IBA; Sumitomo Heavy Industries, Ltd.; Siemens AG; Advanced Cyclotron Systems; ISOSOLUTION; ALCEN; IONETIX Corporation; and Best Cyclotron System, Inc. are among the key players operating in the Medical Cyclotron market.

The report segments the Medical Cyclotron market as follows:

The Medical Cyclotron market is segmented on the basis of type, capacity, and end user. Based on type, the medical cyclotron market is bifurcated into ring cyclotron and azimuthally varying fields (AVF). Based on capacity, the medical cyclotron market is segmented into 10-12 MeV, 16-18 MeV, 19-24 MeV, and 24 MeV and above. Based on end-user, the medical cyclotron market is segmented into hospitals, specialized clinics, pharmaceutical companies, and other end users. By geography, the Medical Cyclotron market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, Africa, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com